Severe Asthma Market

The Severe Asthma market size was valued approximately USD 7.8 billion in 2023 and is anticipated to grow with a rapid CAGR during the study period (2020-2034).

NEVADA, LAS VEGAS, UNITED STATES, June 19, 2024 /EINPresswire.com/ -- DelveInsight’s “Severe Asthma Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Severe Asthma, historical and forecasted epidemiology as well as the Severe Asthma market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Severe Asthma market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Severe Asthma Market Forecast

Some of the key facts of the Severe Asthma Market Report:
The Severe Asthma market size was valued approximately USD 7.8 billion in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
Among the European countries, the United Kingdom had the largest market size, reaching USD 430 million in 2023.
In March 2024, Upstream Bio has initiated patient dosing in its Phase II VALIANT clinical trial of verekitug (UPB-101) for severe asthma. This trial focuses on assessing the effectiveness of verekitug, a recombinant fully human immunoglobulin G1 monoclonal antibody, which works by blocking the thymic stromal lymphopoietin receptor (TLSPR) to counteract TSLP-driven inflammation. The VALIANT trial, conducted in a randomized, double-blind, placebo-controlled manner, spans a 24-week dosing regimen with the goal of determining verekitug's potential as a top-tier treatment option for severe asthma.
In January 2024, GSK has been granted approval by the China National Medical Products Administration for Nucala (mepolizumab) as an additional maintenance treatment for severe eosinophilic asthma in adults and adolescents aged 12 years and older. Nucala, the first-in-class monoclonal antibody that targets anti-interleukin-5 (IL-5), was initially approved in the US in 2015 for severe asthma with an eosinophilic phenotype. Mepolizumab functions by attaching to and blocking IL-5 molecules.
In August 2023, Tezspire (tezepelumab-ekko) is a pioneering human monoclonal antibody designed for additional maintenance therapy for severe asthma in adults and adolescents aged 12 years and older who are unresponsive to their current asthma medications. It stands out as the inaugural biologic choice for severe asthma, regardless of any specific phenotypic or biomarker constraints within its approved usage parameters.
In 2023, the total diagnosed prevalent cases of asthma in the 7MM were approximately 43 million in adults and around 11 million in the pediatric population. These numbers are expected to increase significantly by 2034.
In 2023, the total number of diagnosed prevalent cases of Severe Asthma across the 7MM reached 5.1 million, accounting for roughly 9% of all diagnosed asthma cases. These cases are projected to increase significantly by 2034.
In 2023, the UK had the highest number of diagnosed prevalent cases of Severe Asthma (0.4 million) among the EU4 countries and the UK, followed by France with 0.3 million cases. Conversely, Spain had the lowest number of diagnosed Severe Asthma cases within the same group.
As per DelveInsight analysis, in Japan, the severity-specific cases segmented as intermittent, mild, moderate, and severe cases of asthma were observed to be 4 million, 0.8 million, 1 million, and 0.8 million cases, respectively in 2023. The severity-specific cases are expected to change by 2034.
In 2023, the US had roughly 1.2 million cases of both Type-2 inflammation severe asthma and non-type-2 inflammation severe asthma.
The Severe Asthma pipeline is dynamic and includes promising candidates such as GSK3511294 (Depemokimab) by GlaxoSmithKline, PT010 (Breztri/Trixeo/BGF MDI) by AstraZeneca, among others, anticipated to be launched between 2023 and 2032.
Key Severe Asthma Companies: Teva Pharmaceutical, AstraZeneca, Upstream Bio Inc., Oneness Biotech Co., Chia Tai Tianqing Pharmaceutical, Nantes University Hospital, Hamad Medical Corporation, Incyte Corporation, CSPC ZhongQi Pharmaceutical, AstraZeneca, Sunshine Guojian Pharmaceutical, Amgen, Areteia Therapeutics, Sanofi, GlaxoSmithKline, EMS, Advagene Biopharma Co., Teva Branded Pharmaceutical, and others
Key Severe Asthma Therapies: Cinqair (reslizumab), Fasenra (benralizumab), PT010, Verekitug (UPB-101), FB704A, TQC2731 injection, Benralizumab Prefilled Syringe, Nebulized budesonide, povorcitinib, CM326, CM310, Benralizumab, 610, Rocatinlimab, Dexpramipexole Dihydrochloride, Amlitelimab, GSK3511294 (Depemokimab), Mepolizumab, Flamboyant 200/12, AD17002, TEV-56248, FB825, and others
The Severe Asthma epidemiology based on gender analyzed that females are more susceptible to suffering from asthma when compared to the male population, in the 7MM
The Severe Asthma market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Severe Asthma pipeline products will significantly revolutionize the Severe Asthma market dynamics.

Severe Asthma Overview
Severe asthma is a chronic respiratory condition characterized by persistent and intense symptoms that are difficult to control despite high doses of standard asthma medications. Unlike mild or moderate asthma, severe asthma often requires more aggressive treatment and can significantly impact a person's quality of life.

Get a Free sample for the Severe Asthma Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/severe-asthma-market?utm_source=einpresswire&utm_medium=pressrelease&utm_campaign=gpr

Severe Asthma Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Severe Asthma Epidemiology Segmentation:
The Severe Asthma market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:
Total Prevalence of Severe Asthma
Prevalent Cases of Severe Asthma by severity
Gender-specific Prevalence of Severe Asthma
Diagnosed Cases of Episodic and Chronic Severe Asthma

Download the report to understand which factors are driving Severe Asthma epidemiology trends @ Severe Asthma Epidemiology Forecast

Severe Asthma Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Severe Asthma market or expected to get launched during the study period. The analysis covers Severe Asthma market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Severe Asthma Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Severe Asthma Therapies and Key Companies
Cinqair (reslizumab): Teva Pharmaceutical
Fasenra (benralizumab): AstraZeneca
PT010: AstraZeneca
Verekitug (UPB-101): Upstream Bio Inc.
FB704A: Oneness Biotech Co.
TQC2731 injection: Chia Tai Tianqing Pharmaceutical
Benralizumab Prefilled Syringe: Nantes University Hospital
Nebulized budesonide: Hamad Medical Corporation
povorcitinib: Incyte Corporation
CM326: CSPC ZhongQi Pharmaceutical
CM310: CSPC ZhongQi Pharmaceutical
Benralizumab: AstraZeneca
610: Sunshine Guojian Pharmaceutical
Rocatinlimab: Amgen
Dexpramipexole Dihydrochloride: Areteia Therapeutics
Amlitelimab: Sanofi
GSK3511294 (Depemokimab): GlaxoSmithKline
Mepolizumab: GlaxoSmithKline
Flamboyant 200/12: EMS
AD17002: Advagene Biopharma Co.
TEV-56248: Teva Branded Pharmaceutical
FB825: Oneness Biotech Co.

Severe Asthma Market Strengths
Robust pipeline for severe asthma with potential medicines targeting a variety of different and more effective pathogenic mechanisms in asthma.

Severe Asthma Market Opportunities
To evaluate new candidate pharmacological interventions for severe asthma management in pediatric patient pool for which not many therapies are approved.

Scope of the Severe Asthma Market Report
Study Period: 2020–2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Severe Asthma Companies: Teva Pharmaceutical, AstraZeneca, Upstream Bio Inc., Oneness Biotech Co., Chia Tai Tianqing Pharmaceutical, Nantes University Hospital, Hamad Medical Corporation, Incyte Corporation, CSPC ZhongQi Pharmaceutical, AstraZeneca, Sunshine Guojian Pharmaceutical, Amgen, Areteia Therapeutics, Sanofi, GlaxoSmithKline, EMS, Advagene Biopharma Co., Teva Branded Pharmaceutical, and others
Key Severe Asthma Therapies: Cinqair (reslizumab), Fasenra (benralizumab), PT010, Verekitug (UPB-101), FB704A, TQC2731 injection, Benralizumab Prefilled Syringe, Nebulized budesonide, povorcitinib, CM326, CM310, Benralizumab, 610, Rocatinlimab, Dexpramipexole Dihydrochloride, Amlitelimab, GSK3511294 (Depemokimab), Mepolizumab, Flamboyant 200/12, AD17002, TEV-56248, FB825, and others
Severe Asthma Therapeutic Assessment: Severe Asthma current marketed and Severe Asthma emerging therapies
Severe Asthma Market Dynamics: Severe Asthma market drivers and Severe Asthma market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Severe Asthma Unmet Needs, KOL’s views, Analyst’s views, Severe Asthma Market Access and Reimbursement

To know more about Severe Asthma companies working in the treatment market, visit @ Severe Asthma Clinical Trials and Therapeutic Assessment

Table of Contents
1. Severe Asthma Market Report Introduction
2. Executive Summary for Severe Asthma
3. SWOT analysis of Severe Asthma
4. Severe Asthma Patient Share (%) Overview at a Glance
5. Severe Asthma Market Overview at a Glance
6. Severe Asthma Disease Background and Overview
7. Severe Asthma Epidemiology and Patient Population
8. Country-Specific Patient Population of Severe Asthma
9. Severe Asthma Current Treatment and Medical Practices
10. Severe Asthma Unmet Needs
11. Severe Asthma Emerging Therapies
12. Severe Asthma Market Outlook
13. Country-Wise Severe Asthma Market Analysis (2020–2034)
14. Severe Asthma Market Access and Reimbursement of Therapies
15. Severe Asthma Market Drivers
16. Severe Asthma Market Barriers
17. Severe Asthma Appendix
18. Severe Asthma Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Gaurav Bora
DelveInsight Business Research
+1 469-945-7679
email us here

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.